Immunological therapy: A novel thriving area for triple-negative breast cancer treatment

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies beyond chemotherapy.
• Existing treatments for TNBC include surgery, chemotherapy, endocrine therapy, and molecular targeting therapy.
• Immunotherapy represents a novel treatment modality for TNBC.

Purpose of the Study:

• To review recent research advancements in immunotherapy for TNBC.
• To provide a comprehensive overview of current and emerging immunotherapy strategies for TNBC.

Main Methods:

• Review of recent scientific literature on TNBC immunotherapy.
• Analysis of different immunotherapy approaches including active, passive, and oncolytic immunotherapy.
• Exploration of TNBC molecular classification relevant to immunotherapy.

Main Results:

• Immunotherapy is an emerging treatment for TNBC, distinct from traditional methods.
• Research covers active, passive, and oncolytic immunotherapy strategies.
• Molecular classification of TNBC is crucial for immunotherapy development.

Conclusions:

• Immunotherapy holds significant promise for advancing TNBC treatment.
• Further research into immunotherapy approaches is essential for clinical application.
• The review highlights the evolving landscape of TNBC therapeutic options.